Speaker illustration

Doctor Mason Freeman

CinCor Pharma, Boston (United States of America)

Member of:

European Society of Cardiology

Results from a phase 1 multiple ascending dose study demonstrating safety and selectivity of aldosterone synthase inhibitor CIN-107

Event: ESC Congress 2022

Topic: Pharmacotherapy

Session: Hypertension - Pharmacotherapy

Thumbnail

This platform is supported by

logo Novo Nordisk